Combining vismodegib with radiation may benefit patients with basal cell carcinoma

For most patients with basal cell carcinoma, surgery and radiation have proven to be effective approaches. However, a small subset of patients develop locally advanced basal cell carcinoma, which presents a greater treatment challenge. A single-arm phase II study (NCT01835626), at the University of California San Francisco, is investigating radiation therapy plus the hedgehog pathway inhibitor vismodegib (Erivedge) in patients with locally advanced basal cell carcinoma of the head and neck.